Merck’s Welireg (belzutifan) combined with Keytruda (pembrolizumab) received FDA approval for intermediate-high or high-risk, recurrence-free adjuvant treatment in clear cell renal cell carcinoma following tumor removal surgery. This marks the first FDA nod for a PD-1 plus HIF-2 alpha inhibitor combo in the adjuvant setting. The approval is based on the pivotal Litespark-022 study, where the combination reduced the risk of disease recurrence, metastasis, or death by 28% versus Keytruda plus placebo. The reported disease-free survival estimates were 81% for the Welireg-Keytruda arm versus 74% in the comparator arm, with overall survival results still immature. Clinically, the decision expands Merck’s post-Keytruda trajectory and brings a new standard-of-care option to a risk-stratified population that previously had limited adjuvant choices.